X4 Pharmaceuticals (XFOR) Gets a Buy From Piper Sandler
Buy Rating Affirmed on X4 Pharmaceuticals: A Comprehensive Analysis of Financial Stability and Drug Development Progress
X4 Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $5 Price Target
X4 Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on X4 Pharmaceuticals, Maintains $5 Price Target
X4 Pharmaceuticals (XFOR) Gets a Buy From Piper Sandler
Optimistic Buy Rating for X4 Pharmaceuticals Following FDA Approval and Strong Clinical Prospects
X4 Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5
Buy Rating Affirmed for X4 Pharmaceuticals' Xolremdi on Robust Clinical Efficacy and Favorable Market Strategy
X4 Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $3 Price Target
Buy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor Prospects
B. Riley Securities Downgrades X4 Pharmaceuticals to Neutral, Lowers Price Target to $1
X4 Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN), X4 Pharmaceuticals (XFOR) and Dynatronics (DYNT)
B. Riley Trims X4 Pharmaceuticals' Price Target to $3 From $4, Keeps Buy Rating
HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $3 Price Target
X4 Pharmaceuticals Analyst Ratings